Related Experiment Video

Updated: Jan 15, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.5K

Low adherence of guideline-based monitoring among chronic hepatitis B patients: a mixed quantitative and qualitative

Cui-Ling Huang1, Cheng-Dian Lan1, Ying Yu2

  • 1Department of General Practice, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361006, China.

Journal of Infection in Developing Countries
|January 13, 2026
PubMed

Insights

Adherence to guideline-based monitoring for chronic hepatitis B (CHB) in China is suboptimal, with only 25.6% of patients meeting recommendations. Key barriers include inadequate education, forgetfulness, and cost concerns.

Area of Science:

  • Hepatology
  • Public Health
  • Clinical Medicine

Background:

  • Chronic hepatitis B (CHB) management requires adherence to guideline-based monitoring (GBM).
  • GBM adherence in China's CHB patient population is understudied.
  • Patient-reported barriers to GBM are not well understood.

Purpose of the Study:

  • To assess the adherence rate to GBM among CHB patients in China.
  • To identify factors associated with GBM adherence.
  • To explore patient-reported barriers to GBM.

Main Methods:

  • A mixed-methods study was conducted at Zhongshan Hospital, Fudan University, China.
  • Quantitative data from 402 CHB outpatients (Jan 2018-Dec 2018) included electronic medical records.
  • Qualitative data were gathered through semi-structured interviews and analyzed thematically.

Main Results:

  • Only 25.6% of CHB patients demonstrated good adherence to GBM.
  • Adherence was associated with antiviral treatment and initial liver imaging.
  • Barriers included inadequate health education, forgetfulness, cost, and complex procedures.

Conclusions:

  • Adherence to GBM for CHB patients in China is suboptimal.
  • Interventions should include technology, targeted education, and primary care integration.
  • Improving GBM adherence is crucial for effective CHB management.
Abstract

Keywords:
adherencechronic hepatitis Bmonitoringqualitativequantitative

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.0K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
311
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249